Cargando…

Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial

BACKGROUND: Germ cell tumors (GCT) are the most common solid tumors in adolescent and young adult males (age 15 and 35 years) and remain one of the most curable of all solid malignancies. However a subset of patients will have tumors that are refractory to standard chemotherapy agents. The managemen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Subbiah, Vivek, Meric-Bernstam, Funda, Mills, Gordon B, Shaw, Kenna R Mills, Bailey, Ann Marie, Rao, Priya, Ward, John F, Pagliaro, Lance C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4237879/ https://www.ncbi.nlm.nih.gov/pubmed/25085632 http://dx.doi.org/10.1186/s13045-014-0052-x

Ejemplares similares

Response to sunitinib (Sutent) in chemotherapy refractory clear cell ovarian cancer
por: Alifrangis, C, et al.
Publicado: (2016)

Pharmacokinetics and bioequivalence of sunitinib and Sutent(®) in Chinese healthy subjects: an open-label, randomized, crossover study
por: Wang, Yanli, et al.
Publicado: (2023)

Sunitinib-Containing Carborane Pharmacophore with the Ability to Inhibit Tyrosine Kinases Receptors FLT3, KIT and PDGFR-β, Exhibits Powerful In Vivo Anti-Glioblastoma Activity
por: Alamón, Catalina, et al.
Publicado: (2020)

Immunohistochemical analysis of expression of VEGFR2, KIT, PDGFR-β, and CDK4 in canine urothelial carcinoma
por: Setyo, Laura C., et al.
Publicado: (2023)

Parador turístico sutentable "Tochtli". El Conejo municipio de Perote, Veracruz.
por: Salmerón Becerra, Alan Elias
Publicado: (2017)

PKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GIST
por: Hansson, E K, et al.
Publicado: (2013)

Myelosuppression by sunitinib is flt-3 genotype dependent
por: van Erp, N P, et al.
Publicado: (2010)

Effect of VEGFR, PDGFR and PI3K/mTOR Targeting in Glioblastoma
por: PURCARU, S.O., et al.
Publicado: (2015)

Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations
por: Subbiah, V., et al.
Publicado: (2020)

Screening of FDA-approved drugs identifies sutent as a modulator of UCP1 expression in brown adipose tissue
por: Qiu, Yan, et al.
Publicado: (2018)

Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers
por: Gouda, Mohamed A., et al.
Publicado: (2023)

CanDrA: Cancer-Specific Driver Missense Mutation Annotation with Optimized Features
por: Mao, Yong, et al.
Publicado: (2013)

Precision therapy for RET-altered cancers with RET inhibitors
por: Thein, Kyaw Z., et al.
Publicado: (2021)

Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma
por: Chu, Jie Sheng, et al.
Publicado: (2013)

PDGFRα/β and VEGFR2 polymorphisms in colorectal cancer: incidence and implications in clinical outcome
por: Estevez-Garcia, Purificacion, et al.
Publicado: (2012)

Key Roles for MYC, KIT and RET signaling in secondary angiosarcomas
por: Styring, E, et al.
Publicado: (2014)

Whole Exome Sequencing Identifies PHF14 Mutations in Neurocytoma and Predicts Responsivity to the PDGFR Inhibitor Sunitinib
por: Zhang, Dongyun, et al.
Publicado: (2022)

Flt1/VEGFR1 heterozygosity causes transient embryonic edema
por: Otowa, Yasunori, et al.
Publicado: (2016)

Molecular Characterization of PDGFR-α/PDGF-A and c-KIT/SCF in Gliosarcomas
por: Reis, Rui M., et al.
Publicado: (2005)

Dynamic changes of CSF sPDGFRβ during ageing and AD progression and associations with CSF ATN biomarkers
por: Wang, Jun, et al.
Publicado: (2022)

The Three Receptor Tyrosine Kinases c-KIT, VEGFR2 and PDGFRα, Closely Spaced at 4q12, Show Increased Protein Expression in Triple-Negative Breast Cancer
por: Jansson, Sara, et al.
Publicado: (2014)

Increased PDGFR-beta and VEGFR-2 protein levels are associated with resistance to platinum-based chemotherapy and adverse outcome of ovarian cancer patients
por: Avril, Stefanie, et al.
Publicado: (2017)

Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies
por: Hegde, Aparna, et al.
Publicado: (2020)

Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants
por: Zhao, Jie, et al.
Publicado: (2014)

The VEGFR/PDGFR tyrosine kinase inhibitor, ABT-869, blocks necroptosis by targeting RIPK1 kinase
por: Pierotti, Catia L., et al.
Publicado: (2023)

Whole Genome Sequencing in Cancer Clinics
por: Chen, Ken, et al.
Publicado: (2014)

Hotspot mutations delineating diverse mutational signatures and biological utilities across cancer types
por: Chen, Tenghui, et al.
Publicado: (2016)

TAS‐115 inhibits PDGFRα/AXL/FLT‐3 signaling and suppresses lung metastasis of osteosarcoma
por: Yasuda, Naohiro, et al.
Publicado: (2020)

Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers
por: Adashek, Jacob J., et al.
Publicado: (2021)

Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomy
por: Berardi, Rossana, et al.
Publicado: (2015)

Small Molecular-Sized Artesunate Attenuates Ocular Neovascularization via VEGFR2, PKCα, and PDGFR Targets
por: Zong, Yao, et al.
Publicado: (2016)

Personalized cancer therapy—leveraging a knowledge base for clinical decision-making
por: Dumbrava, Ecaterina Ileana, et al.
Publicado: (2018)

Cancer driver mutation prediction through Bayesian integration of multi-omic data
por: Wang, Zixing, et al.
Publicado: (2018)

Influence of VEGFR single nucleotide polymorphisms on the efficacy of sunitinib therapy against renal cell carcinoma
por: Liu, Rui, et al.
Publicado: (2017)

Synthesis, Characterization and in vitro Studies of a Cathepsin B‐Cleavable Prodrug of the VEGFR Inhibitor Sunitinib
por: Karnthaler‐Benbakka, Claudia, et al.
Publicado: (2018)

GZD824 as a FLT3, FGFR1 and PDGFRα Inhibitor Against Leukemia In Vitro and In Vivo
por: Wang, Yuting, et al.
Publicado: (2020)

Attenuation of VEGFR-2 Expression by sFlt-1 and Low Oxygen in Human Placenta
por: Nevo, Ori, et al.
Publicado: (2013)

Blood Vessel Patterning on Retinal Astrocytes Requires Endothelial Flt-1 (VEGFR-1)
por: Chappell, John C., et al.
Publicado: (2019)

Response to Mammalian Target of Rapamycin–Based Therapy and Incidental Finding of Lynch Syndrome in a Patient With Solid Pseudopapillary Neoplasm of the Pancreas With AKT1_E17K Mutation
por: Cuglievan, Branko, et al.
Publicado: (2018)

Targeting translation initiation in breast cancer
por: Akcakanat, Argun, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_sdn83da76md5fbokuoah3bv9ro